For patients with moderate-to-severe psoriasis, systemic biologic agents targeting tumor necrosis factor-alpha (TNF-alpha) and interleukin 12/23 (IL-12/23) were the first therapies to transform disease management [4]. This evidence concerns the gene TNF and psoriasis.